Login to Your Account

Despite hip win, Cara investors wince at oral CR-845 findings in chronic OA pain

By Marie Powers
News Editor

Friday, June 30, 2017

"This is why you do a phase II," H.C. Wainwright & Co. analyst Corey Davis headlined his note assessing top-line data posted by Cara Therapeutics Inc. on its phase IIb trial of the oral formulation of its peripherally selective kappa opioid agonist, CR-845, in patients with OA of the knee or hip.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription